Who are Jean-Marc /FR Guillaume’s most high-profile connections?
Sign In
Get Started →

Jean-Marc /FR Guillaume

Directeur adjoint USP Bioprocessing chez Sanofi Pasteur
Paris, Ile-de-france, France
Is this your profile? Claim it now
This public profile is provided courtesy of Clay. All information found here is in the public domain.
What is Jean-Marc /FR Guillaume tweeting about?

Jean-Marc /FR Guillaume

Directeur adjoint USP Bioprocessing chez Sanofi Pasteur
Paris, Ile-de-france, France
SummaryAI Assisted Badge

Jean-Marc Guillaume is a highly accomplished professional who has been making waves in the biopharmaceutical industry for more than two decades. He is currently serving as the Directeur adjoint USP Bioprocessing at Sanofi Pasteur, a leading global biopharmaceutical company. In this role, Guillaume is responsible for overseeing the bioprocessing operations of the company, ensuring the quality of the products, and developing processes to improve efficiency and productivity.

Guillaume has a wealth of experience in the biopharmaceutical industry gained from his many years working in different roles at Sanofi Pasteur. In his earlier roles, he worked in process development, quality assurance, and research and development. This experience has given him a deep understanding of the different aspects of the biopharmaceutical industry, from R&D to commercialization.

Guillaume is widely recognized for his exceptional leadership skills, technical expertise, and ability to deliver results. He has played an instrumental role in the development and commercialization of several biopharmaceutical products, including vaccines and pharmaceuticals.

In addition to his work at Sanofi Pasteur, Guillaume is actively involved in the biopharmaceutical industry community. He has been invited to speak at several industry conferences and is a member of various industry organizations.

Overall, Guillaume is a highly respected and accomplished professional who has made significant contributions to the biopharmaceutical industry. His expertise, leadership, and technical knowledge make him a valuable asset to Sanofi Pasteur and the broader biopharmaceutical community.

This public profile is provided courtesy of Clay. All information found here is in the public domain.